CTOs on the Move

ChemDiv

www.chemdiv.com

 
ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contract research organization focused on identifying and delivering discovery opportunities and services for life science partners, and merging industrial and academic efforts to bring new
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.chemdiv.com
  • 6605 Nancy Ridge Dr
    San Diego, CA USA 92121
  • Phone: 858.794.4860

Executives

Name Title Contact Details

Similar Companies

Custom Biogenic Systems

Custom Biogenic Systems is a Romeo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IntegenX

IntegenX is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Contextual Genomics

Transforming cancer care with data driven medicine

AgBiome

AgBiome® partners with the microbial world to improve our planet. AgBiome discovers and develops innovative biological and trait products for crop protection. The proprietary GENESIS™ discovery platform efficiently captures diverse, unique microbes for agriculturally relevant applications, and screens them with industry-best assays for insect, disease, and nematode control. Through its commercial subsidiary, AgBiome develops and sells proprietary crop protection solutions. The first of these, Howler®, is a revolutionary fungicide for disease control in a broad variety of crops.

Gritstone Bio

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.